Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
NORWICH PHARMACEUTICALS, INC. v. BECERRA et al
Case Number:
1:23-cv-01611
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
November 01, 2023
FDA Beats Alvogen Suit Over Xifaxan Skinny Label Rejection
The U.S. Food and Drug Administration was within its right to bar an Alvogen unit from launching its trimmed-down version of Salix's blockbuster drug Xifaxan based on its interpretation of a related court order, a D.C. federal judge said Wednesday.
-
August 18, 2023
Teva Wants In On FDA Suit To Defend Dibs On Xifaxan Generic
Teva Pharmaceuticals should be allowed to protect its generic exclusivity for its version of a Bausch Health unit's blockbuster irritable bowel syndrome treatment, Xifaxan, by intervening in a competitor's suit, the generic-drug giant has told a D.C. federal court.